TROG 17.02 OUTRUN Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (Cat A, Open); Preliminary results + Cognitive Function analysis (#38)
National University Cancer Institute, Singapore, Singapore, SINGAPORE
TROG 17.02 OUTRUN Randomised phase II trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated NSCLC with brain metastases (Cat A, Open); Preliminary results + Cognitive Function analysis